Dupont Capital Management Corp Sells 11,240 Shares of Emergent BioSolutions (EBS)

Dupont Capital Management Corp cut its holdings in shares of Emergent BioSolutions (NYSE:EBS) by 44.1% in the first quarter, Holdings Channel reports. The institutional investor owned 14,253 shares of the biopharmaceutical company’s stock after selling 11,240 shares during the quarter. Dupont Capital Management Corp’s holdings in Emergent BioSolutions were worth $750,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Financial Gravity Companies Inc. purchased a new position in Emergent BioSolutions during the 4th quarter worth approximately $118,000. IFG Advisory LLC purchased a new position in Emergent BioSolutions during the 4th quarter worth approximately $1,050,000. LS Investment Advisors LLC raised its position in Emergent BioSolutions by 183.0% during the 4th quarter. LS Investment Advisors LLC now owns 3,948 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 2,553 shares during the last quarter. GW&K Investment Management LLC purchased a new position in Emergent BioSolutions during the 4th quarter worth approximately $200,000. Finally, Two Sigma Investments LP purchased a new position in Emergent BioSolutions during the 4th quarter worth approximately $223,000. 84.10% of the stock is owned by institutional investors.

In other news, EVP Adam Havey sold 1,898 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $49.50, for a total transaction of $93,951.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ronald Richard sold 7,893 shares of Emergent BioSolutions stock in a transaction on Tuesday, April 17th. The shares were sold at an average price of $55.00, for a total transaction of $434,115.00. Following the completion of the sale, the director now directly owns 31,303 shares in the company, valued at approximately $1,721,665. The disclosure for this sale can be found here. Insiders have sold a total of 15,633 shares of company stock worth $836,640 in the last ninety days. Corporate insiders own 16.50% of the company’s stock.

A number of equities analysts have issued reports on the stock. Wells Fargo reissued a “market perform” rating on shares of Emergent BioSolutions in a research report on Wednesday, April 25th. Zacks Investment Research raised shares of Emergent BioSolutions from a “hold” rating to a “buy” rating and set a $59.00 price target for the company in a research report on Monday, April 30th. Goldman Sachs assumed coverage on shares of Emergent BioSolutions in a research report on Wednesday, January 24th. They set a “neutral” rating and a $55.00 price target for the company. Singular Research raised their price target on shares of Emergent BioSolutions from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, ValuEngine raised shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $56.60.

Shares of Emergent BioSolutions opened at $50.44 on Friday, according to Marketbeat.com. The company has a market cap of $2.45 billion, a PE ratio of 26.55, a PEG ratio of 0.94 and a beta of 1.28. Emergent BioSolutions has a 12 month low of $29.15 and a 12 month high of $55.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.70 and a current ratio of 5.49.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.25). The firm had revenue of $117.80 million for the quarter, compared to analyst estimates of $140.42 million. Emergent BioSolutions had a return on equity of 10.39% and a net margin of 11.96%. Emergent BioSolutions’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.23 EPS. analysts forecast that Emergent BioSolutions will post 2.37 EPS for the current fiscal year.

Emergent BioSolutions announced that its board has initiated a share repurchase plan on Thursday, March 22nd that authorizes the company to repurchase $50.00 million in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent BioSolutions (NYSE:EBS).

Institutional Ownership by Quarter for Emergent BioSolutions (NYSE:EBS)

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply